Multimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.

Simple item page
dc.citation.issue6
dc.citation.volume11
dc.contributor.authorDittmer KE
dc.contributor.authorWetzel S
dc.contributor.authorOdom T
dc.contributor.authorMunday JS
dc.contributor.authorFlatt EA
dc.contributor.authorWilson IJ
dc.contributor.authorHughes C
dc.contributor.authorTan ST
dc.contributor.editorFerreira F
dc.contributor.editorSparger EE
dc.coverage.spatialSwitzerland
dc.date.accessioned2024-07-10T20:23:12Z
dc.date.available2024-07-10T20:23:12Z
dc.date.issued2024-06-17
dc.description.abstractThe renin-angiotensin system (RAS) is increasingly being recognized to play a role in the tumor microenvironment, promoting tumor growth. Studies blocking a single part of the RAS have shown mixed results, possibly due to the existence of different bypass pathways and redundancy within the RAS. As such, multimodal blockade of the RAS has been developed to exert more complete inhibition of the RAS. The aim of the present study was to assess the safety of multimodal RAS blockade in dogs. Five dogs (four with appendicular osteosarcoma, one with oral malignant melanoma) were treated with atenolol, benazepril, curcumin, meloxicam, and metformin. The dogs underwent clinical examination, blood pressure measurement, and hematology and serum biochemistry tests performed at 0, 1, 3, 6, 9, and 12 weeks, then every 3 months thereafter. End-of-life decisions were made by the owners. None of the dogs developed hypotension. One dog had intermittent vomiting during the 64 weeks it was on the trial. One dog had a one-off increase in serum SDMA(symmetrical dimethylarginine) concentration. Dogs were euthanized at weeks 3 (osteosarcoma), 10 (osteosarcoma), 17 (osteosarcoma), and 26 (oral malignant melanoma), and one dog was still alive at the end of the trial at 64 weeks (osteosarcoma). This is the first assessment of multimodal blockade of the RAS in dogs, and the results suggest it causes only mild adverse effects in some animals. The efficacy of the treatment was not assessed due to the small number of dogs. This pilot study allows for future larger studies assessing multimodal RAS blockade for the treatment of canine cancer.
dc.description.confidentialfalse
dc.edition.editionJune 2024
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38922022
dc.identifier.citationDittmer KE, Wetzel S, Odom T, Munday JS, Flatt EA, Wilson IJ, Hughes C, Tan ST. (2024). Multimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.. Vet Sci. 11. 6.
dc.identifier.doi10.3390/vetsci11060275
dc.identifier.eissn2306-7381
dc.identifier.elements-typejournal-article
dc.identifier.number275
dc.identifier.piivetsci11060275
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/70144
dc.languageeng
dc.publisherMDPI (Basel, Switzerland)
dc.publisher.urihttps://www.mdpi.com/2306-7381/11/6/275
dc.relation.isPartOfVet Sci
dc.rights(c) 2024 The Author/s
dc.rightsCC BY 4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectcancer
dc.subjectdog
dc.subjectmelanoma
dc.subjectoncology
dc.subjectosteosarcoma
dc.subjectrenin–angiotensin system
dc.subjecttherapy
dc.titleMultimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.
dc.typeJournal article
pubs.elements-id489573
pubs.organisational-groupCollege of Health
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Published version.pdf
Size:
241.95 KB
Format:
Adobe Portable Document Format
Description:
489573 PDF.pdf
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles